Pfizer to sell its full drug portfolio on not-for-profit basis in low-income countries

U.S. drugmaker Pfizer Inc said on Tuesday it will offer its full portfolio of drugs, including off-patent medicines such as chemotherapies and oral cancer treatments, on a not-for-profit basis to 45 low-income countries in the world.

According to a report by Reuters, this will be a part of an expansion of the Pfizer‘s “An Accord for a Healthier World” program.

Reportedly, the programme is aimed at increasing access to innovative treatments in some of the world’s poorest countries.

Also Read

Pharma retail emerges new frontier for organised players

18 Pharmaceutical companies lose their license over poor quality medicines; Here are the details

This drug works better than caffeine in keeping daytime sleepiness at bay; Here are the details

Pharma major Pfizer asks doctors to stop using these life-saving antibiotics; Here’s why

Pfizer said it will now offer a total of 500 products, as quoted by Reuters.

When the drugmaker launched the programme in May last year, it offered only its patented medicines including COVID-19 treatment Paxlovid and its big-selling breast cancer drug, Ibrance, at a not-for-profit price.

(With inputs from Reuters)